These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 15476401)
1. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Brier S; Lemaire D; Debonis S; Forest E; Kozielski F Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401 [TBL] [Abstract][Full Text] [Related]
2. Use of hydrogen/deuterium exchange mass spectrometry and mutagenesis as a tool to identify the binding region of inhibitors targeting the human mitotic kinesin Eg5. Brier S; Lemaire D; DeBonis S; Kozielski F; Forest E Rapid Commun Mass Spectrom; 2006; 20(3):456-62. PubMed ID: 16402342 [TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877 [TBL] [Abstract][Full Text] [Related]
4. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161 [TBL] [Abstract][Full Text] [Related]
5. S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression. Skoufias DA; DeBonis S; Saoudi Y; Lebeau L; Crevel I; Cross R; Wade RH; Hackney D; Kozielski F J Biol Chem; 2006 Jun; 281(26):17559-69. PubMed ID: 16507573 [TBL] [Abstract][Full Text] [Related]
6. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines. Tcherniuk S; van Lis R; Kozielski F; Skoufias DA Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928 [TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5. Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314 [TBL] [Abstract][Full Text] [Related]
8. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702 [TBL] [Abstract][Full Text] [Related]
9. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity. Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742 [TBL] [Abstract][Full Text] [Related]
10. Photocontrol of mitotic kinesin Eg5 facilitated by thiol-reactive photochromic molecules incorporated into the loop L5 functional loop. Ishikawa K; Tamura Y; Maruta S J Biochem; 2014 Mar; 155(3):195-206. PubMed ID: 24334276 [TBL] [Abstract][Full Text] [Related]
11. Doing the methylene shuffle--further insights into the inhibition of mitotic kinesin Eg5 with S-trityl L-cysteine. Abualhasan MN; Good JA; Wittayanarakul K; Anthony NG; Berretta G; Rath O; Kozielski F; Sutcliffe OB; Mackay SP Eur J Med Chem; 2012 Aug; 54():483-98. PubMed ID: 22749640 [TBL] [Abstract][Full Text] [Related]
12. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation. Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721 [TBL] [Abstract][Full Text] [Related]
13. Loop 5-directed compounds inhibit chimeric kinesin-5 motors: implications for conserved allosteric mechanisms. Liu L; Parameswaran S; Liu J; Kim S; Wojcik EJ J Biol Chem; 2011 Feb; 286(8):6201-10. PubMed ID: 21127071 [TBL] [Abstract][Full Text] [Related]
14. Photocontrol of the mitotic kinesin Eg5 using a novel S-trityl-L-cysteine analogue as a photochromic inhibitor. Ishikawa K; Tohyama K; Mitsuhashi S; Maruta S J Biochem; 2014 Apr; 155(4):257-63. PubMed ID: 24451491 [TBL] [Abstract][Full Text] [Related]
15. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex. Kaan HY; Ulaganathan V; Hackney DD; Kozielski F Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049 [TBL] [Abstract][Full Text] [Related]
16. NSC 622124 inhibits human Eg5 and other kinesins via interaction with the conserved microtubule-binding site. Learman SS; Kim CD; Stevens NS; Kim S; Wojcik EJ; Walker RA Biochemistry; 2009 Mar; 48(8):1754-62. PubMed ID: 19236100 [TBL] [Abstract][Full Text] [Related]
17. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Maliga Z; Kapoor TM; Mitchison TJ Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373 [TBL] [Abstract][Full Text] [Related]
19. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation. Sun L; Sun X; Xie S; Yu H; Zhong D Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354 [TBL] [Abstract][Full Text] [Related]
20. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein. Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]